Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exact Sciences Corporation - Common Stock (NQ: EXAS )

59.40 +3.29 (+5.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
What 8 Analyst Ratings Have To Say About Exact Sciences
Over the past 3 months, 8 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Why Guardant Health Stock Fell 5.5% Today
Is Guardant Health as obvious a bargain as this analyst makes it out to be? 
Via The Motley Fool
8 Analysts Have This to Say About Exact Sciences
Analysts have provided the following ratings for Exact Sciences (NASDAQ:EXAS) within the last quarter: 
Via Benzinga
Amazon, Bank of America, Microsoft And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones gaining around 550 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
3 Growth Stocks That Could Double Your Money, According to Wall Street
Investment bank analysts think these stocks will shoot through the roof once the rest of the market sees them in the same light. 
Via The Motley Fool
Expert Ratings for Exact Sciences
Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Exact Sciences
Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
Upgrades 
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
3 Cathie Wood Stocks That Are Too Cheap to Ignore
These Cathie Wood stocks are risky, but offer immense upside potential down the road, for those willing to take a more aggressive approach. 
Via InvestorPlace
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
Exposures Financial Legal Supply Chain
7 Cheap Cathie Wood Stocks to Buy in October
Ark launched a new fund on Sept. 27. While you try to figure it out, here are 7 cheap Cathie Wood stocks to buy for October. 
Via InvestorPlace
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
7 Nasdaq Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later
Investors should consider buying these Nasdaq stocks on the dip while they still can before the market reverses higher. 
Via InvestorPlace
No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
What 9 Analyst Ratings Have To Say About Exact Sciences
Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
5 Top Stocks Cathie Wood Bought This Week
Cathie Wood continues to increase positions in some of her top stocks despite recession fears. She bought names like EXAS and PACB this week. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund. 
Via Benzinga
Exact Sciences: Q2 Earnings Insights
Exact Sciences (NASDAQ:EXAS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Exact Sciences beat estimated... 
Via Benzinga
Small Cap Biotech Stocks Are Trending Well
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
6 Cathie Wood Stocks to Buy on the Dip
As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. 
Via InvestorPlace
5 Cathie Wood Stocks to Buy in June
These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
Why Ark Innovation ETF Hit 52-Week Lows Today
ARK Innovation ETF (ARCA:ARKK) is making new 52-week lows on Monday, led by sharp declines in the top holdings of Ark's flagship fund. 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Exact Sciences's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94... 
Via Benzinga
SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.